Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs
Jyong Biotech (Nasdaq: MENS) announced a non-binding letter of intent (LOI) with a South Korean pharmaceutical company to evaluate in-licensing and development of its plant-derived investigational drug MCS-2 for the Korean market.
The prospective partner supplies general hospitals and clinics; the LOI is non-exclusive and subject to customary due diligence, regulatory review, negotiation of definitive agreements, and closing conditions. The collaboration would pursue co-commercialization using the partner’s local sales network to accelerate market access if definitive terms are agreed. MCS-2 remains an investigational candidate and is not approved in any jurisdiction. Jyong Biotech said it will provide material updates as developments occur.
Jyong Biotech (Nasdaq: MENS) ha annunciato una lettera di intenti non vincolante (LOI) con una società farmaceutica sudcoreana per valutare l'acquisizione in licenza e lo sviluppo del suo farmaco sperimentale di origine vegetale MCS-2 per il mercato coreano.
Il potenziale partner fornisce ospedali generali e cliniche; la LOI è non esclusiva e soggetta a due diligence abituali, revisione regolamentare, negoziazione di accordi definitivi e condizioni di chiusura. La collaborazione mirerebbe a una co-commercializzazione utilizzando la rete di vendita locale del partner per accelerare l'accesso al mercato se saranno concordati termini definitivi. MCS-2 rimane un candidato investigational non approvato in alcuna giurisdizione. Jyong Biotech ha dichiarato che fornirà aggiornamenti concreti man mano che si verificheranno gli sviluppi.
Jyong Biotech (Nasdaq: MENS) anunció una carta de intenciones no vinculante (LOI) con una compañía farmacéutica surcoreana para evaluar la licencia y el desarrollo de su fármaco experimental de origen vegetal MCS-2 para el mercado coreano.
El socio prospectivo suministra hospitales generales y clínicas; la LOI es no exclusiva y está sujeta a la debida diligencia habitual, revisión regulatoria, negociación de acuerdos definitivos y condiciones de cierre. La colaboración perseguiría una co-comercialización utilizando la red de ventas local del socio para acelerar el acceso al mercado si se acuerdan términos definitivos. MCS-2 continúa siendo un candidato experimental y no está aprobado en ninguna jurisdicción. Jyong Biotech dijo que proporcionará actualizaciones sustantivas a medida que ocurran los avances.
Jyong Biotech (Nasdaq: MENS)는 한국의 제약회사와의 비구속적 의향서(LOI)를 발표하여 식물 유래의 시험용 약물 MCS-2의 국내 시장에 대한 라이선스 대상화 및 개발을 평가합니다.
예상 파트너는 일반 병원과 클리닉에 공급합니다; LOI는 비독점적이며 관례적 실사, 규제 심사, 확정 계약 협상 및 종결 조건에 따릅니다. 협력은 파트너의 현지 판매 네트워크를 활용한 공동 상용화를 추구하여 확정 조건이 합의될 경우 시장 접근을 가속합니다. MCS-2는 여전히 연구 후보이며 어떤 관할 구역에서도 승인되지 않았습니다. Jyong Biotech는 개발 상황에 따라 구체적인 업데이트를 제공할 것이라고 밝혔습니다.
Jyong Biotech (Nasdaq : MENS) a annoncé une lettre d'intention non contraignante (LOI) avec une société pharmaceutique sud-coréenne pour évaluer la cession de licence et le développement de son médicament d'investigation d'origine végétale MCS-2 sur le marché coréen.
Le partenaire potentiel fournit des hôpitaux généraux et des cliniques; la LOI est non exclusive et soumise à la diligence raisonnable habituelle, à l'examen réglementaire, à la négociation d'accords définitifs et aux conditions de clôture. Cette collaboration viserait une co-commercialisation en utilisant le réseau de ventes local du partenaire afin d'accélérer l'accès au marché si des termes définitifs sont convenus. MCS-2 demeure un candidat à l'étude et n'est approuvé dans aucune juridiction. Jyong Biotech a déclaré qu'il fournirait des mises à jour utiles au fur et à mesure que les développements se produisent.
Jyong Biotech (Nasdaq: MENS) gab eine unverbindliche Absichtserklärung (LOI) mit einem südkoreanischen Pharmaunternehmen bekannt, um eine Evaluierung einer Lizenzaufnahme und Entwicklung seines pflanzlich gewonnenen Investigational Drugs MCS-2 für den koreanischen Markt durchzuführen.
Der potenzielle Partner beliefert Allgemeinkrankenhäuser und Kliniken; die LOI ist nicht exklusiv und unterliegt der üblichen Due Diligence, behördlicher Prüfung, Verhandlung endgültiger Vereinbarungen und Abschlussbedingungen. Die Zusammenarbeit würde eine gemeinsame Vermarktung unter Nutzung des lokalen Vertriebsnetzes des Partners anstreben, um den Marktzugang zu beschleunigen, falls endgültige Konditionen vereinbart werden. MCS-2 bleibt ein investigativer Kandidat und ist in keiner Rechtsordnung zugelassen. Jyong Biotech erklärte, dass es bei Entwicklungen fortlaufend relevante Updates geben wird.
Jyong Biotech (Nasdaq: MENS) أعلنت عن وثيقة نوايا غير ملزمة (LOI) مع شركة أدوية كورية جنوبية لتقييم ترخيصه وتطوير دوائه التجريبي المستخرج من النبات MCS-2 لسوق كوريا.
الشريك المحتمل يزود المستشفيات العامة والعيادات؛ وتكون LOI غير حصرية وتخضع للعناية الواجبة المعتادة، والمراجعة التنظيمية، والتفاوض على الاتفاقات النهائية، وشروط الإغلاق. ستسعى الشراكة إلى تعاون تجاري مشترك باستخدام شبكة المبيعات المحلية للشريك لتسريع الدخول إلى السوق إذا تم التوصل إلى شروط نهائية. يبقى MCS-2 کمرشحًا تجريبيًا ولم يتم اعتماده في أي اختصاص. قالت Jyong Biotech إنها ستوفر تحديثات مادية مع تطور الأحداث.
- None.
- None.
Insights
Non‑binding LOI signals regional commercial interest but carries normal execution risk and regulatory uncertainty.
Jyong Biotech has opened formal discussions with a South Korean pharmaceutical company to evaluate in‑licensing and commercialization of MCS-2 in Korea, leveraging the partner's hospital and clinic supply networks. The LOI fits a co‑commercialization model that can speed market entry by using local sales infrastructure and regulatory know‑how while keeping Jyong's development control.
Execution depends on successful due diligence, regulatory review, and definitive agreements; the announcement explicitly notes MCS-2 remains investigational and unapproved in all jurisdictions, which limits near‑term commercial value. Key risks include the non‑binding nature of the LOI, potential failure in regulatory review, and the lack of exclusivity; these factors mean the announcement is an initial commercial step, not a guarantee of revenue.
Watch for concrete milestones: signing of a definitive agreement, any exclusivity or financial terms, completion of regulatory submissions in Korea, and timelines for local clinical or approval activities; expect updates over the next 3–12 months starting from
New Taipei City, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that the Company has entered into a non‑binding letter of intent (the “LOI”) with a South Korean pharmaceutical company to review and evaluate the potential in‑licensing and development of Jyong Biotech’s plant-derived new drug MCS-2for the Korean market. The prospective partner is a recognized supplier to both general hospitals and clinics, and the LOI reflects mutual interest in assessing commercial and regulatory pathways for introducing MCS products in Korea.
This engagement is consistent with Jyong Biotech’s co‑commercialization strategy to collaborate with regional partners that offer established sales networks and local regulatory expertise. Definitive terms are being negotiated between the parties and the partnership, if such definitive terms will be agreed upon, would aim to leverage the partner’s commercial infrastructure to accelerate market access and patient reach in Korea. The LOI is non‑exclusive and subject to customary due diligence, regulatory review, negotiation of definitive agreements, and other closing conditions.
Fu Feng Kuo, Chairwoman of Jyong Biotech, commented: “A selective co‑commercialization approach with strategic partners will enable broader and faster patient access by combining its product development capabilities with partners’ commercial scale and local market knowledge. The Company will work to advance LOI negotiation with these strategic partners and provide updates as material developments occur.”
As of present day, MCS-2 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.
About Jyong Biotech Ltd.
Headquartered in Taiwan, Jyong Biotech Ltd. is a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, BOTRESO®, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers’ health needs and seeks to be a valuable business organization that is held in high esteem by the public.
For more information, please visit: https://www.jyongbio.com/, https://jyongir.com/.
Forward-Looking Statement
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement, prospectuses, annual and interim reports, and other filings with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For more information, please contact:
Jyong Biotech Ltd.
ir@jyongbio.com
Investor Relations
WFS Investor Relations Inc.
Email: services@wealthfsllc.com
Phone: +1 628 283 9214
FAQ
What did Jyong Biotech (MENS) announce on November 24, 2025 regarding MCS-2 in Korea?
Is the LOI between Jyong Biotech (MENS) and the Korean partner exclusive?
What are the next steps after the LOI for Jyong Biotech (MENS) and the prospective Korean partner?
Does the LOI mean MCS-2 is approved for use in Korea or elsewhere?
How would a definitive agreement with the Korean partner affect Jyong Biotech (MENS) commercialization plans?
